GlassScriptPhysician profile
Prathima Moorthy
NPI 1164537973
$3,438.72
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $396 · 2021: $609 · 2022: $469 · 2023: $422 · 2024: $496 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.61 | 2020-2025 | |
| Abbott Laboratories | $305.26 | 2019-2022 | |
| Boston Scientific Corporation | $303.25 | 2024-2025 | Intracept, Intracept Rf Probe, General - Pain Management |
| Collegium Pharmaceutical, INC. | $215.60 | 2019-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $195.45 | 2019-2025 | |
| Pfizer INC. | $188.08 | 2023-2025 | |
| Si-Bone, INC. | $183.23 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $153.12 | 2022 | |
| Fidia Pharma USA INC. | $151.27 | 2020-2023 | Triluron, Hymovis |
| Redhill Biopharma INC. | $120.40 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $92.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $89.98 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.38 | 2019-2020 | |
| Allergan, INC. | $82.54 | 2020-2022 | |
| Almatica Pharma LLC | $65.10 | 2022-2023 | Gralise |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $52.16 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Lilly USA, LLC | $47.98 | 2021-2024 | Reyvow, Emgality |
| Eisai INC. | $44.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.96 | 2019-2023 | Dificid |
| Pacira Therapeutics, INC. | $33.60 | 2021 | |
| Grt US Holding, INC. | $32.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.75 | 2024-2025 | Xifaxan, Relistor |
| Amgen INC. | $24.14 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.01 | 2023 | Zilretta, Iovera |
| Spr Therapeutics, INC | $22.42 | 2024 | Sprint Pns System |
| Nalu Medical, INC. | $21.88 | 2025 | Nalu Neurostimulation System |
| Protega Pharmaceutials INC | $21.28 | 2025 | Roxybond |
| Foundation Fusion Solutions, LLC | $20.78 | 2025 | |
| Zyla Life Sciences, INC. | $18.53 | 2020 | |
| Supernus Pharmaceuticals, INC. | $18.24 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.33 | 2021 | |
| Hikma Pharmaceuticals USA | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathima Moorthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.